Clinical trial · no report yet · Phase 3
SURPASS ET
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
- NCT04285086 ↗
- Active not recruiting
- PharmaEssentia
- 46 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 20 | |
| X threads | 16 | |
| Podcasts | 7 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Essential Thrombocythemia
- Interventions
- Ropeginterferon alfa-2b; Anagrelide
- Arms
- Ropeginterferon alfa-2b (P1101) · Experimental
- Anagrelide · Active comparator
- Enrollment
- 174
- Primary outcomes
- Peripheral blood count remission
- Improvement or non-progression in disease-related signs
- Large symptoms improvement or maintain non-progression
- Absence of hemorrhagic or thrombotic events
- Sponsor
- PharmaEssentia
- Start
- Aug 25, 2020
- Primary completion
- Nov 12, 2024
- Results posted
- No
- Registry record
- NCT04285086 · updated Jul 22, 2026
Publications
linked from the registry- Mesa R, Gill H, Zhang L, Jin J, Kirito K, Komatsu N, Qin A, Xiao Z, Tashi T, Shimoda K, Ohishi K, Chen S, Zuo X, Shirane S, Hu Y, Zhang S, Wang Y, Takenaka K, Ichii M, Xu N, Shih LY, Lim KH, Lee SE, Bae SH, Teo WZY, Maze D, Oh ST, Bose P, Sato T, Zagrijtschuk O, Lin S, Shih WJ, Mascarenhas J, Masarova L; SURPASS-ET Study Group. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol. 2025 Nov;12(11):e862-e875. doi: 10.1016/S2352-3026(25)00264-9. PubMed 41193116
- Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Mesa RA. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep;18(27):2999-3009. doi: 10.2217/fon-2022-0596. Epub 2022 Aug 4. PubMed 35924546